A Genetic Risk-Stratified, Phase II Study of Fludarabine/Antibody Combinations in Symptomatic, Untreated Chronic Lymphocytic Leukemia (CLL): Final Results of Cancer and Leukemia Group B (CALGB) 10404 (Alliance)
   Google Scholar   
Citation:
J. Clin. Oncol. vol 35 (15 suppl) abstr 7503
Meeting Instance:
ASCO 2017
Year:
2017
Type:
Abstract
Sub type:
Oral
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
No
DataSharing:
No
SDC:
Yes
Parents:
None
Children:
2767  
Program:
OGC
Primary Committee:
Leukemia
Sec. Committees:
   
Pharmas:
Celegene  
Grants:
U10CA180820, U10CA180821, U10CA180882, U10CA180828, U10CA180888, NCTN CA180863, CCSRI 021039  
Corr. Author:
 
Authors:
                                   
Networks:
ADM403, ALLIANCE, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-MO011, LAPS-OH007, LAPS-WI020, OR054, PCRC   
Study
CALGB-10404
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords: